FATE THERAPEUTICS INC. - COMMON STOCK

1,2200

05-мая-25 10:19:53

15 мин. задержка

Акции

-0,0900

-6,87%

Сегодняшний диапазон

1,2200 - 1,3250

ISIN

N/A

Источник

NASDAQ

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

09 ноя 2024 12:30:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

08 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

04 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 окт 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

12 сен 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

13 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

31 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 июл 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04 июн 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

29 май 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

09 май 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

06 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

03 май 2024 15:30:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

22 апр 2024 15:30:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

03 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

02 апр 2024 15:01:00 Источник Nasdaq GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

19 мар 2024 07:44:41 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.